NuVasive Portfolio Introduces Low-Profile Modular Implants For Posterior Fixation

The launch of Reline® MAS® Midline delivers procedural versatility in a compact midline construct

SAN DIEGO – July 16, 2018 NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced the launch of Reline MAS Midline (RMM), the next evolution of the Reline system that provides procedural versatility in a compact midline construct.

RMM incorporates extremely low-profile modular implants and advanced system instrumentation to address alignment and potentially reduce adjacent segment transition syndrome. The system, when combined with NuVasive access and interbody technologies, is designed to provide a minimally invasive approach to bilateral decompression under complete visualization, interbody fusion and stabilization with pedicle screws. Delivering screw modularity, RMM allows for greater procedural flexibility while enhancing visibility and access. Furthermore, RMM tulip pull-off strength is comparable to preassembled pedicle screws. Enhanced fixation is achieved with NuVasive’s cortical cancellous traction thread form. The system’s 5.0mm cobalt chrome construct is low in profile and boasts fatigue strength comparable to 5.5mm titanium.

“RMM posterior fixation represents the most advanced midline cortical pedicle screw system on the market,” said minimally invasive spine surgeon Dr. Nitin Khanna, Clinical Faculty of Orthopedic Surgery at the Indiana University School of Medicine and partner at Orthopedic Specialists of Northwest Indiana. “The introduction of modular, low-profile tulip heads was designed to address concerns with adjacent segment facet joint impingement. This system furthers NuVasive’s midline portfolio as best-in-class.”

The NuVasive RMM solution utilizes adaptable, streamlined instruments to support both cortical and standard trajectory techniques. The midline approach is further simplified with the integration of access, interbody and fixation, while modular screw assembly is confirmed with visual and tactile feedback.

“Innovation is in our DNA and we are constantly looking for ways to take our existing solutions to the next level,” said Matt Link, executive vice president, strategy, technology and corporate development for NuVasive. “RMM, a low-profile midline solution that stands out with its versatility, strength and reliability, exemplifies our commitment to innovation and provides relevant solutions to meet the diverse and evolving needs of our surgeons worldwide.”

About NuVasive

NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally-integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With over $1 billion in revenues, NuVasive has an approximate 2,400 person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit

Forward-Looking Statements

NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.



Investor Contact:
Suzanne Hatcher
NuVasive, Inc.
[email protected]


Media Contact:
Scott Nyberg
NuVasive, Inc.
[email protected]


Previous PostNext Post